Board of
Directors
Steve Saviuk
Mr. Saviuk started his career in accounting at KPMG. He quickly moved to venture capital investing through Manitex Capital Inc., a TSXV-listed company he co-founded over 30 years ago, and which still actively invests in emerging companies with a focus on the life science, renewable energy and sustainable resource sectors. Mr. Saviuk is President and CEO of Manitex Capital inc.
Mr. Saviuk co-founded Valeo Pharma in 2003 and has since served as its President and CEO. Mr. Saviuk transformed Valeo Pharma from its early years as an in-licensor of established brands to a fast growing full service Canadian pharmaceutical company and was also instrumental in the sale of certain assets to Valeant Canada. In addition to Mr. Saviuk’s executive management experience, he is well acquainted with key corporate governance issues having served on numerous boards of both public and private companies.
Mr. Saviuk hold a degree in Business (B.Comm) from Concordia University (Montreal, Qc).
Richard J. Mackay
Mr. MacKay has been the Chairman of the Advisory Board of Valeo Pharma Inc. since 2009. He also serves as a Member of Advisory Board at Health Edge Investment Partners. In 2009, Mr. Mackay retired from a distinguished career with Stiefel Laboratories that spanned several decades. During his tenure at Stiefel Laboratories, Mr. MacKay held various leadership positions of increasing responsibility, including, Senior Vice-President, Marketing and Sales North America, Vice President International (Japan and Korea), and most notably as President and CEO of Stiefel Canada from 1976 through 2009. Mr. Mackay also served as Vice Chairman of the Board of Directors of Stiefel Laboratories from 2007-2009.
Prior to Stiefel, Mr. MacKay served as EVP and Director of ICN Canada Limited, VP and Director of Winley-Morris Company Limited and started his career as a sales representative with Parke-Davis Company Limited.
Mr. MacKay was a member of the Board of Labopharm Inc. and served as interim Chairman of the Board for a period of 2 years. He served as Chairman of the Board of the Pharmaceutical Manufacturers Association of Canada (PMAC). Throughout his career, Mr. MacKay has been active in many organizations including member of the Board of Directors of the Canadian Dermatology Foundation, where he served for over 20 years. In 2003, Mr. Mackay was given the first ever Award of Honour by the Canadian Dermatology Association for his service to the people of Canada in raising the standards of health care.
Mr. MacKay is a graduate of Sir George Williams University and earned advanced business diplomas from Harvard University, Dartmouth College and the École des Hautes Études Commerciales (Universite de Montreal).
Richard Lajoie
Richard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams.
Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals.
Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.
Marc Léger
Mr. Léger is a seasoned pharmaceutical executive with pan-Canadian and U.S. experience in both the prescription pharmaceutical and consumer healthcare businesses. He has extensive experience in building and leading organizations and has an excellent track record of developing best in class brands.
Mr. Léger began his career in the pharmaceutical industry in 1984 with Schering Canada as a sales representative in British Columbia. He progressed through the organization in a variety of roles in the marketing and sales departments (Canada and U.S.) leading to the role of Vice President, Primary Care Business Unit (1997-2002) and subsequently to the role of General Manager, Schering-Plough Healthcare Canada (2002-2008), where he led the Consumer Health Business. During his career at Schering-Plough, Mr. Léger was directly involved with the launch and/or development of over 20 brands which became leading brands in their respective markets, and managed and led several organizational structure changes. Mr. Leger has previously served on the Board of Schering Canada Inc.
In February 2009, Mr. Léger joined Valeo Pharma, leading the Commercial Operations where he was directly involved with the development of both the dermatology and specialty products businesses, which were in part sold to Valeant Pharmaceuticals Inc. (now Bausch Health) in 2014. Prior to his retirement from Valeo in 2021, Mr. Léger was acting as Senior VP and Chief Commercial Officer for Valeo.
Mr. Léger graduated from Concordia University (Montreal, Qc) in 1984 with a Bachelor of Arts degree (Economics).
Robert Raich
Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years.
His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning.
Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences.
Charles Bisaillon
Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company.
Mr. Bisaillon graduated from l’École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).